Send us a text

In this episode, Katie Sorensen discusses the hot topic of GLP-1 medications and microdosing. She explains the importance of personalized dosing, the role of compounding pharmacies, and the various health benefits associated with GLP-1s, including weight loss and chronic disease management. The conversation also touches on the future of microdosing and the need for proper medical guidance in using these medications.

Learn more about Katie:

Katie Sorensen, NP-C, is a dedicated Nurse Practitioner and the founder of Weight Loss NP, LLC, a practice committed to helping individuals reclaim their health through personalized, science-backed weight loss and metabolic optimization strategies. With a focus on optimizing cutting-edge treatments like GLP-1 medication therapy and lifestyle strategies to improve long-term results.

Weight Loss NP goes beyond prescriptions—they provide expert care and unwavering support to guide clients toward lasting success.

Learn more about her GLP-1 success course here. Be sure to mention GLP-1 Hub: https://weightlossnp.myflodesk.com/t1flh6id6e

Thank you to our sponsors: 

Visit Gruns.co and use the code GLP1HUBPOD to get up to 52% off your order

Visit our GLP-1 Hub store:

https://www.glp-1hub.com

Get our FREE 7-day meal plans for GLP-1:

7-Day Meal Plan

Plant-based 7-Day Meal Plan

Want to connect more with GLP-1 Hub?

Instagram: https://www.instagram.com/glp1hub

Tiktok: https://www.tiktok.com/@glp1hub

YouTube: https://www.youtube.com/@glp-1hub

Weekly newsletter with weight loss tips and podcast updates: https://glp1hub.myflodesk.com/rn9j3lxjpp

*Some of the links shared are affiliate links. When you make a purchase, I will receive a small commission at no cost to you. Thank you for supporting the show.

*The content of this show is for informational purposes only and does not constitute medical advice. The goal of this show is to provide various points of view about GLP-1 Medications. The personal and professional opinion of the guests and their content does not necessarily reflect the opinion of Ana Reisdorf or GLP-1 Hub.